TickerHumSide-by-side comparison
Johnson & Johnson vs Pfizer
As of Nov 11, 2026, P/E is 42.3x for Johnson & Johnson vs 41.8x for Pfizer; P/S is 6.7x for Johnson & Johnson vs 2.6x for Pfizer; revenue growth is 7.8% for Johnson & Johnson vs 1.3% for Pfizer; net margin is 16.2% for Johnson & Johnson vs 6.3% for Pfizer.
What stands out
- Johnson & Johnson carries less debt relative to equity: 0.44 vs 0.67 for Pfizer.
- Johnson & Johnson's shares did better over the past year: +43.2% vs +13.2% for Pfizer.
Key metrics
| Metric | JNJ | PFE |
|---|---|---|
| Price | $278.45 | $29.28 |
| Market cap | $670.32B | $166.86B |
| P/E | 42.3x (#2) | 41.8x (#1) |
| P/S | 6.7x (#2) | 2.6x (#1) |
| Revenue growth | 7.8% (#1) | 1.3% (#2) |
| Operating margin | — | — |
| Net margin | 16.2% (#1) | 6.3% (#2) |
| Debt / equity | 0.44 (#1) | 0.67 (#2) |
| 1-year return | +43.2% (#1) | +13.2% (#2) |
| Research score | 60/100 (#1) | 51/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Johnson & Johnson (JNJ) — Drug Manufacturers—General
- Pfizer Inc. (PFE) — Drug Manufacturers—General